Continuous Infusion of Low-dose Doxorubicin, Epirubicin and Mitoxantrone in Cancer Chemotherapy: a Review

Overview

Journal Pharm Weekbl Sci

Specialty Pharmacy

Date 1988 Dec 9

PMID 3062572

Citations 5

Authors

J Greidanus

P H Willemse

D R Uges

E T Oremus

Z J de Langen

E G De Vries

Affiliations

Soon will be listed here.

Abstract

With the recent development of reliable portable pumps and safe venous access systems, continuous infusion of chemotherapeutic agents on an out-patient basis has become feasible. Advantages of continuous infusion are the long-term exposure of tumour cells to the drug and the fact that most toxic effects are reduced for doxorubicin, epirubicin and mitoxantrone due to elimination of the high peak plasma levels. Preliminary data for doxorubicin suggest that its antitumour activity is maintained. Pharmacokinetic studies with epirubicin and mitoxantrone showed a linear relationship between drug dose infused and the steady-state plasma level for these drugs. The area under the curve for leukocytes drug level was higher during continuous infusion than after an equitoxic bolus injection of epirubicin and mitoxantrone. Well-randomized clinical trials will be necessary to investigate the role of continuous infusion of antracyclines and mitoxantrone in cancer chemotherapy in the future.

Citing Articles

Adjusting the Structure of β-Cyclodextrin to Improve Complexation of Anthraquinone-Derived Drugs.

Krzak A, Swiech O, Majdecki M, Garbacz P, Gwardys P, Bilewicz R Molecules. 2021; 26(23).

PMID: 34885787 PMC: 8659250. DOI: 10.3390/molecules26237205.

Anthraquinone-2-sulfonic acid (AQ2S) is a novel neurotherapeutic agent.

Jackson T, Verrier J, Kochanek P Cell Death Dis. 2013; 4:e451.

PMID: 23303125 PMC: 3563977. DOI: 10.1038/cddis.2012.187.

Comparison of doxorubicin concentration profiles in radiofrequency-ablated rat livers from sustained- and dual-release PLGA millirods.

Qian F, Stowe N, Saidel G, Gao J Pharm Res. 2004; 21(3):394-9.

PMID: 15070087 DOI: 10.1023/B:PHAM.0000019290.70358.30.

Bayesian estimation of doxorubicin pharmacokinetic parameters.

Bressolle F, Ray P, Jacquet J, Bres J, GALTIER M, Donadio D Cancer Chemother Pharmacol. 1991; 29(1):53-60.

PMID: 1742849 DOI: 10.1007/BF00686336.

Stability and compatibility of four anthracyclines: doxorubicin, epirubicin, daunorubicin and pirarubicin with PVC infusion bags.

Dine T, CAZIN J, Gressier B, Luyckx M, Brunet C, Cazin M Pharm Weekbl Sci. 1992; 14(6):365-9.

PMID: 1475177 DOI: 10.1007/BF01970174.

References

Ganzina F . 4'-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. Cancer Treat Rev. 1983; 10(1):1-22. DOI: 10.1016/s0305-7372(83)80029-2. View

Frederiksen P, Joergensen S, Roesdahl K, Thomsen J, Mouridsen H . Activity of adriamycin in metastatic breast cancer resistant to a combination regimen with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prdnisone. Cancer Treat Rep. 1978; 62(3):449-50. View

Smith I . Optimal schedule for anthracyclines. Eur J Cancer Clin Oncol. 1985; 21(2):159-61. DOI: 10.1016/0277-5379(85)90167-1. View

Lokich J, Bothe Jr A, Benotti P, Moore C . Complications and management of implanted venous access catheters. J Clin Oncol. 1985; 3(5):710-7. DOI: 10.1200/JCO.1985.3.5.710. View

Shenkenberg T, Von Hoff D . Mitoxantrone: a new anticancer drug with significant clinical activity. Ann Intern Med. 1986; 105(1):67-81. DOI: 10.7326/0003-4819-105-1-67. View

Jain K, Casper E, Geller N, Hakes T, Kaufman R, Currie V . A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol. 1985; 3(6):818-26. DOI: 10.1200/JCO.1985.3.6.818. View

Pacciarini M, Barbieri B, Colombo T, Broggini M, Garattini S, Donelli M . Distribution and antitumor activity of adriamycin given in a high-dose and a repeated low-dose schedule to mice. Cancer Treat Rep. 1978; 62(5):791-800. View

Nieweg R, Greidanus J, De Vries E . A patient education program for a continuous infusion regimen on an outpatient basis. Cancer Nurs. 1987; 10(4):177-82. DOI: 10.1097/00002820-198708000-00003. View

Lokich J, Becker B . Subclavian vein thrombosis in patients treated with infusion chemotherapy for advanced malignancy. Cancer. 1983; 52(9):1586-9. DOI: 10.1002/1097-0142(19831101)52:9<1586::aid-cncr2820520908>3.0.co;2-4. View

10.

Carlson R, Sikic B . Continuous infusion or bolus injection in cancer chemotherapy. Ann Intern Med. 1983; 99(6):823-33. DOI: 10.7326/0003-4819-99-6-823. View

11.

Smith I . Mitoxantrone (novantrone): a review of experimental and early clinical studies. Cancer Treat Rev. 1983; 10(2):103-15. DOI: 10.1016/0305-7372(83)90008-7. View

12.

Greenblatt D, Koch-Weser J . Clinical pharmacokinetics (second of two parts). N Engl J Med. 1975; 293(19):964-70. DOI: 10.1056/NEJM197511062931905. View

13.

Vogelzang N, Ruane M, Ratain M, Dhowlatshahi K, Chodak G . A programmable and implantable pumping system for systemic chemotherapy: a performance analysis in 52 patients. J Clin Oncol. 1987; 5(12):1968-76. DOI: 10.1200/JCO.1987.5.12.1968. View

14.

Zijlstra J, De Vries E, Mulder N . Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res. 1987; 47(7):1780-4. View

15.

Lokich J, Bothe A, Fine N, Perri J . Phase I study of protracted venous infusion of 5-fluorouracil. Cancer. 1981; 48(12):2565-8. DOI: 10.1002/1097-0142(19811215)48:12<2565::aid-cncr2820481204>3.0.co;2-e. View

16.

Mouridsen H, Bastholt L, Somers R, Santoro A, Bramwell V, Mulder J . Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol. 1987; 23(10):1477-83. DOI: 10.1016/0277-5379(87)90089-7. View

17.

Sikic B, Collins J, Mimnaugh E, Gram T . Improved therapeutic index of bleomycin when administered by continuous infusion in mice. Cancer Treat Rep. 1978; 62(12):2011-7. View

18.

Lokich J . Phase I study of cis-diamminedichloroplatinum(II) administered as a constant 5-day infusion. Cancer Treat Rep. 1980; 64(8-9):905-8. View

19.

Di Marco A, Gaetani M, SCARPINATO B . Adriamycin (NSC-123,127): a new antibiotic with antitumor activity. Cancer Chemother Rep. 1969; 53(1):33-7. View

20.

Weenen H, Lankelma J, Penders P, McVie J, Ten Bokkel Huinink W, de Planque M . Pharmacokinetics of 4'-epi-doxorubicin in man. Invest New Drugs. 1983; 1(1):59-64. DOI: 10.1007/BF00180192. View